Editor's Note: BioWorld has always kept a watchful eye on big pharma developments as they relate to the biotech space. Now we're making it easier for readers by separating pharma business and clinical news into these columns of brief news.

• Abbott, of Abbott Park, Ill., said the European Committee for Medicinal Products for Human Use issued a positive opinion for Humira (adalimumab) in adults with moderate to severely active ulcerative colitis who have not responded to, cannot tolerate or have medical contraindications to conventional therapies. A final decision from the European Commission is anticipated in a few weeks.

No Comments